MedTrace Logo

Initial Study Sesting Efficacy and Tolerability of PT150 for PTSD in Veterans

NCT07187011 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-23

No results posted yet for this study

Summary

The purpose of this study is to test the drug PT150, which blocks glucocorticoid receptor (GR) signaling, for treatment of PTSD in Veterans, and establish a safety and efficacy profile that will inform the design of future studies.

Conditions

  • PTSD - Post Traumatic Stress Disorder

Interventions

DRUG

PT150

Glucorticoid antagonist 900 mg

DRUG

Placebo

900 mg

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Pop Test Oncology LLC

    collaborator INDUSTRY

  • San Diego Veterans Healthcare System

    lead FED

Principal Investigators

  • Victoria Risbrough, PhD · San Diego VA Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2029-03-01
Completion
2029-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187011 on ClinicalTrials.gov